Prolactinoma in males: a single center experience in Northern Africa.

The Spectrum of Serum Prolactin Levels in Patients with Non-Functioning Sellar Masses: A Retrospective Analysis.

The clinical value of [18F]-fluoro-ethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study.

Sex differences in the clinical presentation, management and long-term outcomes of pituitary tumors in children and adolescents.

Surgery for prolactinoma.

Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report.

p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas.

Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas.

Dopamine agonist withdrawal in patients with prolactinoma.

LATE DIAGNOSIS OF ACROMEGALY IN THE SETTING OF A SOMATOPROLACTINOMA.

Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.

Impact of sex on mortality in patients with pituitary adenomas.

Hypopituitarism in patients with prolactinomas: a narrative review.

Cavernous Sinus Medial Wall Resection: A Retrospective Single-Institution Study on Outcomes in Functional Pituitary Adenomas.

Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic.

Dopamine Agonist Therapy Induced Fatal Pneumocephalus in Giant Prolactinoma.

A novel germline CDH23 variant as a likely cause of an ultra-giant prolactinoma.

The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response?

Surgical Outcomes in Knosp Grade 3 or 4 Macroprolactinomas: What Role Does Debulking Surgery Play?

Widespread invasion of a giant prolactinoma via valveless venous channels: illustrative case.

Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group.

Endoscopic Endonasal Transsphenoidal Surgery (EETS) for PitNETs: Outcomes in a Single Institution Over a Decade.

Fertility and pregnancy in patients with prolactinoma.

Endoscopic surgery for noninvasive prolactinomas: A large multicenter, single-arm, retrospective study (PRLomaSaR).

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas.

Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes.

The usefulness of cannulated prolactin test in mild hyperprolactinemia: case series and systematic review of the literature.

Giant Prolactinoma: Challenges in Management.

Management for prolactinomas of postmenopausal female patients: a retrospective single-center study.

The diagnostic dilemma of idiopathic granulomatous mastitis with an emphasis on histopathologic findings.

Pituitary Apoplexy: A Case Series.

Rising burden of PRL-PitNETs: patterns across tumour sizes and incidentalomas.

Aggressive Macroprolactinoma Refractory to Multiple Lines of Localized and Systemic Therapy.

Correlation between serum endocrine hormone levels and malignancy degree of prolactinoma and their predictive value for patient prognosis.

Cerebrospinal fluid fistula following dopamine agonist therapy in giant prolactinomas: A case series and review of the literature.

Endoscopic endonasal surgery for prolactin-secreting adenoma: a retrospective multicenter study by the neuroendoscopy section of the Italian Society of Neurosurgery.

Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up.

High-Risk Prostate Cancer in a Patient with Untreated Prolactinoma and Castrate-Level Testosterone Suppression: A Case Report.

Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up.

Case Report: Management of a pregnancy complicated by a symptomatic macroprolactinoma.

Therapeutic challenges of giant invasive cystic macroprolactinoma.

Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery.

Endocrine Comorbidities in Fibromyalgia.

Autonomic balance and cardiovascular hemodynamic function in men with prolactinoma.

Approach to the Patient With Dopamine-Resistant Microprolactinoma.

Loss of heterozygosity and absence of MAX immunostaining in a prolactinoma associated with multiple endocrine neoplasia type 5 (MEN5).

Aggressive prolactinomas in men are associated with visual disturbances and pituitary hormone deficiencies.

[Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)].

[Clinical management of pituitary prolactinoma from the perspective of obstetrics and gynecology: from reproductive health to lifespan care].

[Clinical practice considerations on cabergoline in the treatment of pituitary prolactinoma].

[Refractory pituitary prolactinoma:current treatment status and challenges].

[The evolving role of surgery in the management of pituitary prolactinomas].

[Interpretation of key updates in the "Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)"].

Multiparameter MRI-based clinical-radiomic model to differentiate prolactinoma from hyperprolactinemic nonfunctioning pituitary adenoma.

Management of a mixed ACTH- and prolactin-secreting pituitary adenoma during pregnancy.

Cystic versus non-cystic prolactinoma: clinical, hormonal, radiological, and remission outcomes in Basrah.

Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?

Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K/AKT/CREB3L1 pathway and ornithine decarboxylase.

Management outcomes of prolactinoma: a retrospective study from Southern Iraq.

Prevalence and Risk Factors of Dopamine Agonists Induced Impulse Control Disorders in Patients With Prolactinoma.

Immunohistochemical Comparison of Dopamine-2 Receptor Expression in Resistant and Non-Resistant Prolactinomas.

Stiff-person syndrome mimic secondary to hypopituitarism: a case report and literature review.

Challenges in the Management of Silent Lactotroph Pituitary Adenoma.

Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment.

Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study.

Dynamic changes in IGF-1 levels during cabergoline therapy in prolactinoma.

Secondary Loss of Response to Dopamine Receptor Agonists in the Treatment of Macroprolactinoma.

Rare Occurrence of Distant Metastases in Prolactinoma: Insights From 2 Cases and Review of the Literature.

Profile of pituitary adenoma in patients from rural areas: A study at Dr. Saiful Anwar hospital, Indonesia, 2024.

Debate: Surgery as Initial Therapy for Microprolactinoma.

How to Define Success in Prolactinoma Treatment-A Systematic Review and Theoretical Framework.

An 18-year Odyssey: navigating the complex path of prolactinoma management: a case report.

Risk-Stratifying Pituitary Adenoma Treatment: A Cohort Analysis and Risk Prediction of Hypopituitarism.

Prolactin secreting pituitary neuroendocrine tumors treated by dopamine agonists: predictors of response.

Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages.

Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists.

A new and useful tool for differentiating prolactinomas from non-functioning pituitary adenomas: a pilot study of the cabergoline disconnection test.

Paeoniflorin attenuates hyperprolactinemia by targeting the pituitary mPRα-mediated, dopamine receptor-independent signaling in vivo and in vitro.

Prolactinomas and Knosp grade: when is surgery the appropriate choice? A systematic review and meta-analysis.

The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort.

Identifying Hub Genes Associated with Sex Disparities in Prolactinomas.

Cabergoline-induced prolactinoma treatment and subsequent estrogen-driven vascular smooth muscle tumorigenesis in a middle-aged female: A case report.

Urinary incontinence as a novel and underrecognized clinical manifestation of prolactinoma in women.

Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.

Lipid Profile Differences in Monomeric Hyperprolactinemia, Macroprolactinemia, and Healthy Controls: A Comparative Analysis.

Prolactin impairs erectile function via eNOS suppression independently of testosterone.

Evaluating pituitary tumor management: aligning with pituitary tumor centers of excellence criteria.

Hypogonadism in men with prolactinoma: Diagnosis, treatment, and management of persistent hypogonadism.

When the fog lingers: persistent cognitive and emotional burden in patients with a prolactinoma despite disease control.

Comprehensive Comparison of Visual Outcomes in Macro and Giant Prolactinoma Cohorts Managed With Medical Versus Surgical Treatment.

Epidemiologic Profile and Clinical Outcomes of Adult Patients with Prolactinoma at the Philippine General Hospital.

Thyroid Scan Conundrum in a Rare Case of McCune-Albright Syndrome.

Novel germline likely pathogenic frameshift variant of the MEN1 gene contributes to multiple endocrine neoplasia type 1: a case report with review of literature.

Differential expression of PTEN, pAKT1, pRPS6, and mismatch repair proteins in pituitary neuroendocrine tumors.

Giant Pituitary Adenoma Presenting with Craniovertebral Junction Instability: A Case Report and Review of Literature.

Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta-Analysis.

Prolactinoma Resection in a Transgender Woman on Gender-affirming Hormone Therapy.

Anemia in Patients With Pituitary Adenomas: Prevalence and Correlation With Hypopituitarism.

"Just Got Diagnosed; What Worked for You?": A Mixed-Methods Analysis of Treatment Experiences in the Prolactinoma Subreddit.

Microbiome and metabolic disorder in prolactinoma: intrinsic gender differences and extrinsic therapy effects.

Giant Prolactin-Secreting Pituitary Adenoma: A Case Report and Literature Review.

Endoscopic endonasal transcavernous surgery for a contemporary series of 59 prolactinomas.

High-dose Hook Effect in a Case of Giant Prolactinoma Confounded by Acute Kidney Injury.

Estimating diagnostic delay in patients with pituitary adenomas in Sweden: a cross-sectional study.

Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia.

Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity?

Hyperprolactinemia caused by extra-pituitary prolactin secretion: a systematic review.

Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis.

Subtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control.

Advances in Drug Treatments for Male Patients with Prolactinomas.

Genetic association of AIP gene variant c.910C>T with pituitary adenomaacromegaly patients of Pakistani origin.

Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review.

Successful diagnosis and monitoring of giant prolactinomas: the role of sample dilutions.

Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis.

Examining the viability of modern endoscopic endonasal surgery as a first-line treatment for macroprolactinomas: a multicentric study on the results and significance of the highest preoperative prolactin level in predicting long-term surgical outcomes.

Hyperprolactinemia and cancer risk: a Swedish population-based cohort study.

Impulse control disorders in pituitary adenoma: What do we know and what we still don't know in almost two decades?

Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway.

Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors.

Hyperprolactinemia in children and adolescents: clinical characteristics and etiological spectrum.

The effect of hyperprolactinemia and its treatment on oxidative stress.

Impact of Tumor Size on Prolactinoma Characteristics and Treatment Outcomes: A Study of a Tunisian Cohort.

Cabergoline monotherapy in polycystic ovary syndrome patients with elevated prolactin: a viable option?

Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors.

Elevated Dehydroepiandrosterone Sulfate Levels in 2 Patients With Prolactinomas: An Underrecognized Association.

MicroRNA Is Downregulated in Invasive Non-Functioning Pituitary Adenomas.

Soluble alpha klotho-impact of biological variables and reference intervals for adults.

Cabergoline-induced cerebrospinal fluid fistulae in macroprolactinomas.

Pediatric Pituitary Adenomas and Cysts: A 46-Year Population-Based Analysis.

Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy-How Concerned Should We Be?

Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance.

Navigating prognostic strategies for GH- and PRL-secreting pituitary neuroendocrine tumors: key insights from a clinicopathological study.

Intracavitary Yttrium-90 Colloid Therapy for Cystic Sellar Masses: A Phase II Clinical Trial With 5-Year Follow-Up.

Functional Suppression of a Prolactinoma by a Dopamine-Secreting Paraganglioma.

Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.

The contribution of prolactin in the occurrence of premature cardiovascular disease predominantly through modulating the inflammatory cascade.

Pulmonary Fibrosis in a Patient With a Prolactinoma on Dopamine Agonists: Coincidence or Consequence.

Double pituitary adenoma associated with acromegaly and hyperprolactinemia: a case report.

Transcriptomic analysis of the anti-tumor effects of leflunomide in prolactinoma.

Circulating miR-20a-5p as a biomarker associated with cabergoline responsiveness in patients with hyperprolactinemia and pituitary adenomas.

Resistant PRL-secreting PitNET associated with breast carcinoma: a case report and literature review.

Multiple endocrine neoplasia type 1 in childhood and description of a novel variant.

Cabergoline Use and Pregnancy Outcomes: A Systematic Review.

Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations.

Ectopic dopamine agonist-resistant macroprolactinoma to the clivus masquerading as a chordoma - A case report.

Reassessing the role of the p.(Arg304Gln) missense AIP variant in pituitary tumorigenesis.

Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas.

Menopause Has a Beneficial Influence on the Evolution of Prolactinomas. A Study of 99 Patients.

Dopamine agonists and weight changes in prolactinoma patients.

Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.

A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies.

Double PitNETs: A Case Report and Literature Review.

miR-21-5p Targets PIK3R1 to Regulate the NF-κB Signaling Pathway, Inhibiting the Invasion and Progression of Prolactinoma.

Arrested Puberty in a Young Adult With a Macroprolactinoma: Case Report and Literature Review.

Multiple Endocrine Neoplasia Type 1 With Adrenal Cortical Adrenocortical Carcinoma: A 25-Year Follow-Up and Family Report.

Ovarian cancer causing hyperprolactinemia: A case report and narrative review.

Ischemic stroke risk in patients with dopamine agonist-treated hyperprolactinemia.

Headache in pituitary adenomas: frequency, characteristics and outcome after treatment.

Prolactin-secreting pituitary carcinomas with intra- and extracranial metastasis: case report and review.

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas.

Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.

Outcomes in surgical management of microprolactinomas: an international multi-institutional series.

Exploring sex-specific hematological changes and their impact on quality of life in patients with prolactinoma.

Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale.

Etiology, presentation, and outcomes of hyperprolactinemia due to pituitary masses in children and adolescents.

Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance.

Conservative medical therapy for a macroprolactinoma presenting with obstructive hydrocephalus.

Psychological burden in patients with sellar masses under conservative and surgical management.

A rare case of double pituitary prolactinomas: the diagnostic application of intraoperative ultrasonography and DNA methylation markers.

Cabergoline Induced Pathological Gambling in an Adolescent with Prolactinoma.

Determinants of cerebrospinal fluid leakage in a large cohort of macroprolactinomas.

Gonadotropic axis following endoscopic surgery for pituitary neuroendocrine tumor in patients of reproductive age.

Hyperprolactinemia complicated with peliosis hepatis: One case report and review of literature.

Correlation between MRI findings of pituitary gland and prolactin level among hyperprolactinemia adult female Saudi patients in rural areas: A retrospective multicentric study.

Screening with Metoclopramide Test to Reduce Unnecessary Pituitary Magnetic Resonance Studies in Moderate Hyperprolactinemia.

RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly.

Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.

Pharmacological management of pituitary adenomas - what is new on the horizon?

Polycystic Ovary Syndrome in the Context of Pituitary Adenomas: Prevalence, Pathophysiology and Clinical Management.

Giant prolactinoma with progressive cranial settling and central herniation: a case report.

Pituitary adenomas in children: surgical course and functional outcome. Lille cohort retrospective study.

Incidence of postoperative cerebrospinal fluid leaks in endoscopic endonasal transsphenoidal surgery for pituitary adenomas without sellar floor reconstruction: A retrospective observational study from a low-middle-income country.

MicroRNA networks in prolactinoma tumorigenesis: a scoping review.

Multiple Eyelid Apocrine Hidrocystomas in a Patient With Prolactinoma.

The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2.

Zuyangping formula promotes skin wound healing in diabetic rats.

Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009-2022.

Disease Activity and Maternal-fetal Outcomes in Pregnant Women With Prolactinoma: A Systematic Review and Meta-analysis.

Spontaneous Cerebrospinal Fluid Rhinorrhea in Pre-operative Pituitary Adenoma: A Report of Two Cases.

Diagnostic Utility of the Prolactin Decrease Rate in the Diagnosis of Mild Hyperprolactinemia.

Clinical Features and Hormonal Profile of Macroprolactinomas Presenting With the Hook Effect: A Systematic Review.

Modern approach to bone comorbidity in prolactinoma.

[Efficacy of standard methods in the treatment of prolactin-secreting pituitary carcinoma].

Mass Spectrometric and Immunologic Detection of Prolactin-Derived Vasoinhibin in Human Serum.

Reframing the Paradigm: A Nuanced Approach to Prolactinoma Management.

Clinical parameters and postoperative outcomes of pituitary adenomas in children: Analysis according to size of adenomas and adopted surgical procedures.

B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance.